A survey among dermatologists: diagnostics of superficial fungal infections – what is used and what is needed to initiate therapy and assess efficacy?
Background Superficial fungal infections are common. It is important to confirm the clinical diagnosis by mycological laboratory methods before initiating systemic antifungal treatment, especially as antifungal sensitivity and in vitro susceptibility may differ between different genera and species....
Saved in:
Published in: | Journal of the European Academy of Dermatology and Venereology Vol. 33; no. 2; pp. 421 - 427 |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
England
01-02-2019
|
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Background
Superficial fungal infections are common. It is important to confirm the clinical diagnosis by mycological laboratory methods before initiating systemic antifungal treatment, especially as antifungal sensitivity and in vitro susceptibility may differ between different genera and species. For many years, the gold standard for diagnosis of superficial fungal infections has been direct fungal detection in the clinical specimen (microscopy) supplemented by culturing. Lately, newer molecular based methods for fungal identification have been developed.
Objective
This study was initiated to focus on the current usage of mycological diagnostics for superficial fungal infections by dermatologists. It was designed to investigate whether it was necessary to differentiate between initial diagnostic tests and those used at treatment follow‐up in specific superficial fungal infections.
Methods
An online questionnaire was distributed among members of the EADV mycology Task Force and other dermatologists with a special interest in mycology and nail disease.
Results
The survey was distributed to 62 dermatologists of whom 38 (61%) completed the whole survey, 7 (11%) partially completed and 17 (27%) did not respond. Nearly, all respondents (82–100%) said that ideally they would use the result of direct microscopy (or histology) combined with a genus/species directed treatment of onychomycosis, dermatophytosis, Candida‐ and Malassezia‐related infections. The majority of the dermatologists used a combination of clinical assessment and direct microscopy for treatment assessment and the viability of the fungus was considered more important at this visit than when initiating the treatment. Molecular based methods were not available for all responders.
Conclusion
The available diagnostic methods are heterogeneous and their usage differs between different practices as well as between countries. The survey confirmed that dermatologists find it important to make a mycological diagnosis, particularly prior to starting oral antifungal treatment in order to confirm the diagnose and target the therapy according to genus and species. |
---|---|
Bibliography: | Funding sources None. Conflict of interests DMS has received consultant fee for advisory board meeting by AbbVie, Jannsen Pharma and Sanofi and as a speaker for Bayer, Galderma, Astellas, Abbvie and Leo Pharma. RJH has been a consultant for Mayne Pharma, Polychem and Janssen Pharma. PN has received consultant fee for advisory board meeting by Galderma and as a speaker for Almirall Hermal, Galderma, Janssen Pharma, Pfizer, MSD, and Beiersdorf. BMP has received consultant fee for advisory board meeting by Polichem, Legacy Healthcare and Pfizer and as a speaker for ISDIN, Giuliani, Avangarde and Almirall. JF has been consulting for Moberg Pharma, Mylan and Galderma. AYS has received consultant fee for advisory board meetings by Janssen‐Cilag, Novartis and Dr Reddy's, and as a speaker for Astellas, Bayer, Galderma, Glenmark, MSD and Pfizer. JCS has been consultant and advisor for AbbVie, Celgene, Dignity Sciences, Leo Pharma, Novartis, Pierre‐Fabre, Sienna Pharmaceuticals and Sandoz. He has also been investigator for AbbVie, Actelion, Amgen, GSK, Janssen, Merck, Novartis, Regereron, Takeda, Trevi and speaker for AbbVie, Actavis, Janssen, Leo Pharma, Novartis, SunFarm, Sandoz, Eli Lilly. PSG, RJN, CR‐C, MA, MS, AP, PL, BS, LE declares no conflict of interest. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0926-9959 1468-3083 1468-3083 |
DOI: | 10.1111/jdv.15361 |